CAS Medical’s technology “provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making,” said Katie Szyman, Edwards' corporate vice president, critical care, in a statement.
Biogennix, an Irvine-based maker of bone graft substitutes, appointed Robert Baizer as its first chief financial officer.
NextGen Healthcare Inc. (Nasdaq: NXGN), the biggest publicly traded health care software provider based in Orange County, reported fiscal third quarter adjusted profit of 18 cents, which topped analyst expectations of 15 cents.
Spectrum Pharmaceutical Inc. (Nasdaq: SPPI) said today it has sold its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma LLC for up to $300 million.
Shares of Edwards Lifesciences Corp. (NYSE: EW) climbed after the largest publicly traded company based in Orange County reached a settlement with rival Boston Scientific Corp. (NYSE: BSX).
DEVELOPMENT: SmartHome site eyed for congregate care
A Dallas-based developer of senior living properties has bought a 3-acre site along Barranca Parkway in Irvine, and plans to start construction later this year on one of the city’s largest and amenity-heavy residential complexes for older residents.
Mission Viejo-based MYnd Analytics Inc. (Nasdaq: MYND) appointed Patrick Herguth as chief executive officer, replacing George Carpenter who will assume the new role of chief innovation officer.
Late Tuesday, Judge David Carter ordered a second hearing, set for Thursday, before he will sign off on James Mazzo’s agreement with the Securities and Exchange Commission to settle insider trading charges.
Shares of Skyworks Solutions Inc. are down after the chipmaker provided December quarter revenue and earnings targets below Wall Street expectations.
Alteryx Inc. reported revenue increased 59% year-over-year to $54.2 million while posting a narrower loss of $244,000, compared to a loss of $3.3 million in the same period a year ago.
Masimo Corp. (Nasdaq: MASI) reported third quarter revenue climbed 8.9% to $210.6 million. Product sales grew 12% to $202.1 million for the quarter while royalty and other revenue declined 38% to $8.5 million.
Edwards Lifesciences Corp. (NYSE: EW) earned $226 million on sales of $907 million in its most recent quarter. Sales rose 10% year-over-year but missed expectations and its shares dipped 2% to a $30 billion market cap.
Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) named Francois Lebel as chief medical officer, overseeing the company’s clinical program including directing clinical trials and development as well as regulatory submissions.